Welcome to our dedicated page for Contineum Therapeutics news (Ticker: CTNM), a resource for investors and traders seeking the latest updates and insights on Contineum Therapeutics stock.
Contineum Therapeutics, Inc. (CTNM) generates a steady flow of news as a clinical-stage biopharmaceutical company focused on novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications. News coverage for CTNM often centers on clinical trial milestones, topline data readouts and capital markets activity related to its lead programs PIPE-791 and PIPE-307.
Investors following CTNM news can expect updates on clinical development, including Phase 1b and Phase 2 trials in idiopathic pulmonary fibrosis, multiple sclerosis, chronic pain and major depressive disorder. The company has reported positive topline data from a Phase 1b PET trial of PIPE-791, topline results from the PIPE-307 VISTA Phase 2 trial in relapsing-remitting multiple sclerosis, and regular progress reports on planned global Phase 2 studies in idiopathic pulmonary fibrosis.
Contineum’s news flow also includes financial results and financing transactions. The company issues quarterly financial updates and has announced both at-the-market offerings and underwritten public offerings of Class A common stock, including an upsized public offering under an effective shelf registration statement. These items provide context on how Contineum funds its research and development plans.
Additional CTNM headlines cover investor conference participation, regulatory and trial design disclosures, and collaborations such as the global license and development agreement with Janssen Pharmaceutica NV for PIPE-307. For readers tracking the CTNM stock, this news page offers a centralized view of material events, clinical data announcements and corporate developments affecting Contineum Therapeutics.
Contineum Therapeutics (NASDAQ: CTNM) announced positive topline data from its Phase 1b PET trial of PIPE-791, a novel brain penetrant LPA1 receptor antagonist. The trial demonstrated that PIPE-791 achieved high brain receptor occupancy (RO) in both healthy volunteers and progressive multiple sclerosis (PrMS) patients.
Key findings include plasma EC50 values of 37 ng/mL at 24 hours and 12 ng/mL at 168 hours post-dose, demonstrating sustained target engagement. The company expects planned doses for future Phase 2 trials in idiopathic pulmonary fibrosis (IPF) and PrMS to exceed 90% target coverage with once-daily dosing.
The trial involved 12 healthy volunteers and 4 PrMS patients, showing a clear correlation between drug exposure and receptor engagement, with a safety profile consistent with previous studies.
Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on neuroscience, inflammation and immunology (NI&I) therapies, has announced its participation in three major healthcare investor conferences in September 2025.
The company will participate in fireside chats at the Cantor Global Healthcare Conference on September 4 at 9:10 a.m. ET, the Morgan Stanley Global Healthcare Conference on September 8 at 8:30 a.m. ET, and the Baird Global Healthcare Conference on September 9 at 2:00 p.m. ET. All presentations will be available via webcast on Contineum's investor relations website.
Contineum Therapeutics (NASDAQ: CTNM) has reported its Q2 2025 financial results and clinical development updates. The company ended Q2 with $175.5 million in cash and projects runway through 2027, supplemented by $8.4 million raised through ATM offering in July 2025.
Key milestones include anticipated topline data from PIPE-307 Phase 2 VISTA trial for multiple sclerosis in Q4 2025, and initiation of a global Phase 2 trial for PIPE-791 in idiopathic pulmonary fibrosis. The company reported a net loss of $16.0 million in Q2, with R&D expenses increasing 78% to $14.1 million year-over-year.
To optimize resources, Contineum has postponed its planned PIPE-791 Phase 2 trial in progressive multiple sclerosis and CTX-343 first-in-human studies to focus on the IPF program.
Contineum Therapeutics (NASDAQ: CTNM) has provided an update on its Phase 1b PET trial of PIPE-791, a selective LPA1 receptor antagonist. The company has completed enrollment for healthy volunteer and progressive multiple sclerosis (PrMS) cohorts, with 12 healthy volunteers and 4 PrMS patients enrolled to date.
The trial aims to assess the correlation between pharmacokinetics and LPA1 receptor occupancy using PET imaging. Due to the addition of two PrMS patients in early June, the company now expects to report topline data in Q3 2025, representing a modest delay. Enrollment for idiopathic pulmonary fibrosis (IPF) patients is still ongoing.
ArrePath (NASDAQ:CTNM) has announced the successful completion of a new financing round led by Boehringer Ingelheim Venture Fund, with participation from existing investors Insight Partners, Innospark, Nor'easter Ventures, and new investor AB Magnitude. The funding, combined with non-dilutive awards from PACE and CARB-X, will support the advancement of their lead program AP-001 and expand their antimicrobial compound development.
Additionally, the company has appointed Dr. Diego Miralles as the new Chair of the Board of Directors. Dr. Miralles brings extensive biotech and pharmaceutical industry experience, having served as CEO of multiple companies including AZURNA Therapeutics, Laronde, and Vividion Therapeutics, and held senior positions at Johnson & Johnson.
Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on developing therapies for neuroscience, inflammation and immunology (NI&I) conditions, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, May 20th at 8:30 a.m. ET. Investors and interested parties can access the audio webcast through the Investors section of Contineum's website, where a replay will also be made available.
Contineum Therapeutics (NASDAQ: CTNM) has appointed Timothy Watkins, M.D., M.Sc. as its new Chief Medical Officer and Head of Development. Dr. Watkins, formerly Vice President at Gilead Sciences, brings extensive experience in immunology and fibrotic disease therapeutic development.
Key highlights:
- Dr. Watkins succeeds Stephen L. Huhn, who served as CMO since 2020
- Company plans to initiate Phase 2 clinical trial for idiopathic pulmonary fibrosis in second half of 2025
- Dr. Watkins received inducement awards including: - Time-based stock option for 260,000 shares - Performance-based stock option for 26,000 shares
The appointment aligns with Contineum's enhanced focus on inflammation, immunology, and fibrotic disease development. The company's pipeline includes PIPE-307 for multiple sclerosis and depression, developed in partnership with Johnson & Johnson.
Contineum Therapeutics (NASDAQ: CTNM) has appointed Diego Miralles, M.D. to its Board of Directors, effective March 14, 2025. Dr. Miralles, currently CEO of AZURNA Therapeutics, brings extensive experience in novel therapy development and clinical trials.
Dr. Miralles' career includes leadership roles at Laronde Inc. (2020-2022), Vividion Therapeutics (2017-2020), and Johnson & Johnson (2007-2016). He currently serves on the board of Artiva Biotherapeutics and chairs its Clinical Strategy Committee. His academic background includes an M.D. from the University of Buenos Aires, residency at Mayo Clinic, and fellowship at The New York Hospital/Cornell University.
Contineum, a clinical-stage biopharmaceutical company, focuses on developing therapies for neuroscience, inflammation, and immunology (NI&I) indications. The company is preparing to initiate multiple proof-of-concept clinical trials.
Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on developing therapies for neuroscience, inflammation and immunology (NI&I) conditions, has announced its upcoming participation at the Stifel 2025 Virtual CNS Forum.
The company's management will deliver a presentation on Tuesday, March 18th at 12:30 p.m. ET. Interested parties can access the audio webcast through the Investors section of Contineum's website, where a replay will also be made available.